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Neuromyelitis optica (NMO) is a rare syndrome of severe inflammatory demyelination of the central nervous system, causing
attacks of optic neuritis and transverse myelitis. Although uncommon, attention should be given to the proper identification
and management of the affected patients. We present a case of a 13-year-old girl with severe neuromyelitis optica. The patient’s
initial presentation consisted of encephalopathy and optic neuritis. Approximately 2 months later, coinciding with the weaning of
steroid treatment, she presented with ascending paralysis and respiratory failure. She was seropositive for NMO-IgG. Treatment
included intravenous immune globulin, steroids, plasmapheresis, and rituximab and was complemented with proper nutrition,
vitamins, minerals, and intense rehabilitation. Two years after the initial presentation and one short relapse, the patient has made
a remarkable recovery without neurologic deficit. This report underscores the difficulty in making the initial diagnosis, choosing
the best treatment, and the need for more streamlined pediatric guidelines for diagnosis, treatment, and prevention of relapses of
pediatric NMO.

1. Introduction
Neuromyelitis optica (NMO), otherwise known as Devic
Disease, is an uncommon clinical syndrome of central
nervous system inflammatory demyelination, comprising of
optic neuritis and transverse myelitis. First accounts to this
disorder date back to the 1870s [1]. Although once believed
a variant of other disorders like multiple sclerosis, acute
demyelinating encephalomyelitis (ADEM), systemic lupus
erythematosus, Sjögren’s syndrome, and connective tissue
disorders, as well as association with viral and bacterial
infections [2], specific diagnostic criteria have now been
proposed for NMO, making it a clinically distinct syndrome
[3]. Early recognition of NMO is important for specific management options and proper patient and family counseling. If
undiagnosed, NMO may lead to unnecessary investigations

and treatments, recurrent and prolonged hospital course,
significant morbidity, and even death. We report this case
to show a protracted course of the disease, diagnostic and
treatment difficulties, and to raise awareness about this rare
disorder among pediatricians who are usually first involved
in the care of these children.

2. Case Presentation
2.1. First Admission. A 13-year-old African American girl
presented to the hospital with a 6-day history of fatigue,
weakness, upper back and shoulder pain, subjective fever,
decreased appetite, and weight loss. She was previously
healthy. On examination, she was encephalopathic with
waxing and waning mental status, flat affect, ophthalmoparesis, with decreased visual acuity, and color agnosia.
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During hospitalization, the patient’s symptoms worsened
with episodes of vomiting, periods of agitation, and at times
unresponsiveness to environmental stimuli.
The initial brain MRI showed increased signal in the
hypothalami, mammillary bodies, periaqueductal gray matter, and posterior aspect of pons and medulla, raising a
question about Wernicke’s encephalopathy. Subsequent MRIs
showed progression of abnormalities with new enhancement
of bilateral optic nerves extending to the optic chiasm,
pontine tegmentum bilaterally, and gradual resolution of
earlier appeared changes (Figure 1).
EEG showed bilateral slowing consistent with encephalopathy.
The cerebrospinal fluid (CSF) examination showed
157 WBC/mm3 with 95% lymphocytes. Aquaporin-4 receptor
antibody in serum was negative.
Patient was treated with intravenous immune globulin
(IVIG), 2 doses (1 g/kg) over a 48-hour period and thiamine for suspected Wernicke’s encephalopathy based on the
presence of encephalopathy clinically and suggestive MRI
findings. Subsequent thiamine level was normal and she
had not improved with thiamine treatment. Secondary to
worsening clinical condition, patient was started on a 5-day
course of intravenous methylprednisolone (30 mg/kg for 3
days, then 15 mg/kg for 2 days), followed by a 5-week oral
prednisone taper. The patient responded to steroid treatment
with significant improvement in her mental status, vision, and
musculoskeletal exam. She was also diagnosed with latent
tuberculosis based on positive QuantiFERON-TB Gold test
(with negative PPD and chest X-ray) and started on a 9month treatment regimen with isoniazid and pyridoxine. It
was undetermined whether latent tuberculosis was related to
her illness. After a 2-month inpatient stay, including 1 month
of rehabilitation, she was discharged home on prednisone
taper, multivitamins, and minerals with continued outpatient
rehabilitation.
2.2. Second Admission. Approximately 1.5 months later,
patient presented to the emergency room with a two-week
history of progressive paresthesias, leg weakness, and bladder
and bowel dysfunction. Patient decompensated quickly and
progressed to quadriplegia, respiratory failure, and altered
mental status. She required intubation and mechanical ventilation for 8 days in the intensive care unit.
MRI of the spine showed increased signal throughout
most of the cervical and thoracic spine, with central cord
enlargement, and heterogeneous and patchy areas of central
and peripheral enhancement (Figures 2(a)–2(c)). MRI of the
brain was normal this time. Abnormal lab findings were:
NMO-IgG antibodies positive in CSF and serum; positive
EBV by PCR (119 copies/mL in CSF and 136 copies/mL in
serum), EBV IgG positive, EBV IgM negative; low copper
level of 60 (75–187 mcg/dL), and positive ANA screen.
At this point, the patient was diagnosed with seropositive
neuromyelitis optica.
Treatments included IV methylprednisolone at 1 to 2
grams daily for 7 days, 1 dose of IVIG at 1 g/kg, plasmapheresis
on alternate days for 7 days, and IV cupric chloride (1.2 mg
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daily for approximately 2 weeks) as a copper supplement, as
well as a multivitamin with mineral daily. She also received
4 treatments of rituximab at 375 mg/m2 , given every other
week, outpatient.
After about 2 months of inpatient care, she was transferred to the inpatient rehabilitation service for therapies.
At the time of discharge, 3.5 months after the second
admission, her visual acuity and color agnosia had improved,
she had regained partial use of her upper extremities and
some improvement in sensation of lower extremities but still
with paraplegia, requiring manual wheelchair for mobility
and motorized wheelchair only in school. She also had
some awareness of her bowel/bladder function, although
remained incontinent. Medications on discharge included
slow prednisone taper, gabapentin for pain, rituximab weekly
to complete 4 doses, and multivitamin with minerals. She
continued outpatient rehabilitation. The MRIs 10 months
later showed normal brain and cervical cord spine while
thoracic cord showed T2 signal abnormalities with minimal
residual patchy enhancement in mid and lower thoracic cord.
2.3. Third Admission. She was in outpatient rehab for 6.5
months and at the time of discharge walked independently
without any assistance. She continued doing well for another
5 months except for some episodic urinary incontinence
and then had a relapse with mild right-sided weakness
and numbness. MRI brain was normal, cervical MRI was
markedly abnormal with new cord enlargement at C2 and
C3 with associated abnormal enhancement. Thoracic cord
remained unchanged from examination 6 months earlier.
Repeated CSF examination was normal except for elevated
myelin basic protein to 15.3 𝜇L (nl 0.0–4.0 𝜇L). She was
treated with 3 doses of methylprednisolone, followed by 4
doses of rituximab at 375 mg/m2 given weekly. She made a
remarkable recovery and, 5 months after the relapse, she is
neurologically completely normal, does well in school, and
wants to be a pediatric neurologist. She received the first
preventive treatment 7 months after the last one while her
total B-cell count was low: CD19 absolute count < 20 cells/𝜇L
(nl 130–180) or 1% of normal.

3. Discussion
Proposed diagnostic criteria for NMO in children require
the following features: optic neuritis, myelitis, and one of
the following: MRI evidence of a contiguous spinal cord
lesion three or more segments in length or seropositivity
for NMO-IgG. NMO-IgG autoantibody that selectively binds
to the aquaporin-4 (AQP4) water channel is thought to be
a specific marker for NMO [4]. It is present in over 70
percent of those with NMO and in a smaller percentage
of other demyelinating CNS disorders, including multiple
sclerosis [5]. In patients who meet these criteria, some other
CNS involvement beyond the optic nerves and spinal cord is
compatible with NMO [4].
The clinical course of NMO is variable. It may occur
as a monophasic illness that is either fulminant and fatal
or associated with varying degrees of recovery. Pediatric
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Figure 1: MRI of the brain: (a) axial T1W postcontrast: enhancement of bilateral optic nerves extending to the optic chiasm. (b) and (c): T2W
FLAIR: increased signal in a symmetric fashion involving the hypothalami, mammillary bodies, periaqueductal gray matter, and posterior
aspect of pons and medulla.

(a)

(b)

(c)

Figure 2: MRI of the cervical spine: (a) T1W postcontrast shows increased cord signal with an enlarged, edematous central cord. MRI of the
thoracic spine: (b) T2W STIR shows abnormal T2 signal within the cord. MRI of the lumbar spine: (c) T1W postcontrast with fat suppression
shows abnormal enhancement in the cord.

cases typically have a monophasic course and many have
complete neurological recovery [2, 6]. Polyphasic courses
characterized by relapses and remissions also occur. Our
patient was diagnosed with seropositive NMO upon second
presentation with myelitis. It is likely that our patient has had
biphasic presentation with the first phase being encephalopathy and optic neuritis and the second phase with myelitis and
encephalopathy.
In the pediatric population, NMO is frequently preceded
by infection. Positive CSF and blood for EBV in our patient
was suspicious of being a causative factor.
There are no specific guidelines for NMO treatment. At
present, the mainstay of therapy is the treatment of acute

attacks, prevention of medical complications, and rehabilitation. Specific medications that have been used include:
methylprednisolone with prednisone taper, immunosuppressants such as azathioprine [7, 8], cyclophosphamide [8, 9],
and rituximab [10, 11], and plasmapheresis [12–15]. Rituximab
is a murine/human monoclonal antibody directed against
CD20 that induces B-cell depletion when administered in
vivo. It is approved by the FDA for the treatment of CD20+
lymphomas and rheumatoid arthritis. Its selective depletion
of the humoral component of the immune system makes it an
attractive and more effective approach for treating NMO [11].
The rapid succession of various treatments in our patient with
rituximab being last, and supplement with cupric chloride for

4
low copper level, makes it difficult to determine which one
combination was the best one and decreased her disability.
She responded very well to rituximab during a short-lived
relapse 15 months after the diagnosis of NMO was made.
We choose rituximab for the prevention of relapses in this
patient. Although at present she is completely normal, this
outcome did not come easily nor timely and her future
remains uncertain.

4. Conclusion
This case report should serve as an example of the difficulties
pediatricians and neurologists encounter caring for children
with NMO. Furthermore, it calls for establishing diagnostic
criteria and evidence-based guidelines for the treatment and
relapse prevention of pediatric NMO.
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Written informed consent was obtained from the parent
of this patient for publication of this case report and any
accompanying images. A copy of the written consent is
available for review.
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